Definitive Management of Malignant Phyllodes of the Breast
The American Surgeon™ · 2025
DOI: 10.1177/00031348251412264 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The American Surgeon™, 2025. Verfasst von Casey A Hamlet und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Rutgers New Jersey Medical School, Newark, NJ, USA. Hauptthemen laut MEDLINE: Phyllodes Tumor, Breast Neoplasms. Die Arbeit nennt 42 Literaturangaben.
Abstract (Originalsprache)
Background
Malignant phyllodes tumors (MPT) are rare, aggressive fibroepithelial breast neoplasms with limited consensus on optimal management. While wide local excision (WLE) with ≥1 cm margins is standard, recurrence remains common, and the role of adjuvant therapy remains unclear.
Methods
We conducted a 28-year retrospective review of 14 histologically confirmed MPTs in 11 patients at a single urban safety-net hospital. Clinical, pathologic, and treatment data were analyzed to assess recurrence, metastasis, and treatment outcomes.
Results
The median tumor size was 7.6 cm. Most patients (73%) presented with stage II disease. Surgical management included WLE alone (45.5%), WLE with radiation (27.3%), mastectomy alone (9.1%), and mastectomy with adjuvant radiation (18.2%). Local recurrence occurred in 3 patients (27.3%), all of whom were initially treated with surgery alone. Those who recurred received adjuvant radiation; no recurrences occurred after adjuvant radiation. One patient developed metastases and received systemic chemotherapy. Only 1 patient underwent genetic testing, which revealed a TP53 mutation.
Conclusions
Recurrence occurred often despite margin-negative resections, highlighting the limitations of current surgical guidelines and the potential importance of tumor biology. These findings support a more individualized treatment approach that incorporates histologic features and, when appropriate, genetic testing. Adjuvant radiation may reduce the risk of recurrence in high-risk cases, although our small cohort precludes definitive conclusions. These findings should be considered hypothesis-generating and highlight the need for prospective or registry-based studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Rutgers New Jersey Medical School, Newark, NJ, USA.
- Rutgers New Jersey Medical School, Newark, NJ, USA.
- Department of Radiation Oncology, Rutgers Cancer Institute, New Brunswick, NJ, USA.
- Department of Hematology & Oncology, Rutgers New Jersey Medical School, Newark, NJ, USA.
- Department of Pathology, Rutgers New Jersey Medical School, Newark, NJ, USA.
ORCID-Profile: Casey A Hamlet, Hima Bindu Thota, Susan E Pories
Zitieren
APA
Hamlet, C. A., Thota, H. B., Daria, E. B., Zieba, D. J., Mattes, M. D., Shah, A. S., Suster, D. I., & Pories, S. E. (2025). Definitive Management of Malignant Phyllodes of the Breast. The American Surgeon™. https://doi.org/10.1177/00031348251412264
Vancouver
Hamlet CA, Thota HB, Daria EB, Zieba DJ, Mattes MD, Shah AS, et al. Definitive Management of Malignant Phyllodes of the Breast. The American Surgeon™. 2025. doi:10.1177/00031348251412264
BibTeX
@article{Hamlet2025,
author = {Hamlet, Casey A and Thota, Hima Bindu and Daria, Emi B and Zieba, Denise J and Mattes, Malcolm D and Shah, Ankit S and Suster, David I and Pories, Susan E},
title = {Definitive Management of Malignant Phyllodes of the Breast},
journal = {The American Surgeon™},
year = {2025},
doi = {10.1177/00031348251412264}
}
EUVIMED